Core Viewpoint - Cumberland Pharmaceuticals Inc. will announce its 2025 financial results and provide a company update on March 3, 2026, after market close, followed by a conference call to discuss the results [1] Company Overview - Cumberland Pharmaceuticals is a specialty pharmaceutical company focused on developing, acquiring, and commercializing products for hospital acute care, gastroenterology, and oncology market segments [1] - The company’s portfolio includes several FDA-approved products such as Talicia®, Vibativ®, Vaprisol®, Sancuso®, Kristalose®, Caldolor®, and Acetadote® [1] Product Details - Talicia® is an oral capsule for treating H. pylori infection - Vibativ® is an injection for serious bacterial infections, including hospital-acquired pneumonia - Vaprisol® is an injection used to raise serum sodium levels in hospitalized patients - Sancuso® is a transdermal system for preventing nausea and vomiting in chemotherapy patients - Kristalose® is a prescription laxative for treating constipation - Caldolor® is an injection for pain and fever management - Acetadote® is an injection for treating acetaminophen poisoning [1] Clinical Programs - The company is conducting Phase II clinical programs for its ifetroban product candidate, targeting conditions such as Systemic Sclerosis, cardiomyopathy associated with Duchenne Muscular Dystrophy, and Idiopathic Pulmonary Fibrosis [1]